Aigen Investment Management, LP Xencor Inc Transaction History

Aigen Investment Management, LP

  • $487 Million
  • Q3 2024

A detailed history of Aigen Investment Management, LP transactions in Xencor Inc stock. As of the latest transaction made, Aigen Investment Management, LP holds 13,670 shares of XNCR stock, worth $324,389. This represents 0.06% of its overall portfolio holdings.

Number of Shares
13,670
Previous 14,734 7.22%
Holding current value
$324,389
Previous $278,000 1.44%
% of portfolio
0.06%
Previous 0.06%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024
SELL
$15.7 - $21.65 $16,704 - $23,035
-1,064 Reduced 7.22%
13,670 $274,000
Q2 2024

Aug 09, 2024
BUY
$18.21 - $24.5 $268,306 - $360,983
14,734 New
14,734 $278,000
Q4 2023

Feb 09, 2024
BUY
$16.53 - $21.42 $613,725 - $795,281
37,128 Added 352.32%
47,666 $1.01 Million
Q3 2023

Nov 13, 2023
SELL
$20.08 - $25.39 $76,866 - $97,192
-3,828 Reduced 26.65%
10,538 $212,000
Q2 2023

Aug 14, 2023
BUY
$24.77 - $29.9 $125,930 - $152,011
5,084 Added 54.77%
14,366 $358,000
Q1 2023

May 15, 2023
BUY
$25.95 - $36.95 $240,867 - $342,969
9,282 New
9,282 $258,000
Q4 2020

Feb 12, 2021
SELL
$36.63 - $47.63 $165,018 - $214,573
-4,505 Closed
0 $0
Q3 2020

Nov 06, 2020
BUY
$30.09 - $43.02 $135,555 - $193,805
4,505 New
4,505 $175,000
Q2 2020

Aug 10, 2020
SELL
$27.76 - $33.42 $582 - $701
-21 Closed
0 $0
Q1 2020

May 08, 2020
SELL
$20.69 - $37.79 $37,842 - $69,117
-1,829 Reduced 98.86%
21 $1,000
Q4 2019

Feb 04, 2020
BUY
$32.75 - $41.43 $60,587 - $76,645
1,850 New
1,850 $64,000

Others Institutions Holding XNCR

# of Institutions
216
Shares Held
71.8M
Call Options Held
2.5K
Put Options Held
7.9K
View Full List

About Xencor Inc

XNCR Quotes by TradingView
  • Ticker XNCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,698,100
  • Market Cap $1.42B
  • Description
  • Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...
More about XNCR
Track This Portfolio

Track Aigen Investment Management, LP Portfolio

Follow Aigen Investment Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aigen Investment Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Aigen Investment Management, LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email